Renovorx Inc Stock Price, News & Analysis

RenovoRx (Nasdaq: RNXT) reported strong Q2 2025 results, with RenovoCath® device revenue reaching $422,000. The company's independent Data Monitoring Committee (DMC) recommended continuing the pivotal Phase III TIGeR-PaC trial following a positive interim data review. As of June 30, 2025, RenovoRx had $12.3 million in cash, with 95 patients randomized and 61 events recorded in the trial.

The company has expanded its RenovoCath commercialization, with thirteen cancer center customers approved for device purchase, up from five in Q1 2025. Four centers have used the device with repeat orders. RenovoRx estimates an initial $400 million peak annual U.S. sales opportunity for RenovoCath as a standalone device, with potential for multi-billion-dollar TAM through additional applications.

Financial results showed a net loss of $2.9 million for Q2 2025, compared to $2.4 million in Q2 2024. R&D expenses decreased to $1.4 million from $1.5 million year-over-year, while SG&A expenses remained stable at $1.5 million.

RenovoRx (NASDAQ:RNXT) announced significant expansion of its commercialization efforts for its RenovoCath® FDA-cleared drug-delivery device. The company has grown its customer base to thirteen cancer centers, including several National Cancer Institute (NCI)-designated and community centers, up from five centers in Q1 2025.

Four active customers are currently using RenovoCath and have placed repeat orders. The company has also appointed Philip Stocton as Senior Director of Sales and Market Development, bringing over 25 years of MedTech experience to lead commercialization efforts.

RenovoRx expects additional growth potential from 18 cancer centers currently participating in its Phase III TIGeR-PaC trial, which is anticipated to complete enrollment by early 2026. The RenovoCath device enables targeted locoregional delivery of chemotherapy through the company's Trans-Arterial Micro-Perfusion (TAMP) therapy platform.

RenovoRx (NASDAQ:RNXT) has launched PanTheR, a multi-center post-marketing registry study to evaluate its FDA-cleared RenovoCath® device for targeted cancer treatment delivery. The study will commence patient enrollment before September 2025, with the University of Vermont Cancer Center as the first clinical site.

The PanTheR study aims to collect real-world data on RenovoCath's long-term safety and survival outcomes in patients with solid tumors. Participating cancer centers will purchase RenovoCath devices directly from RenovoRx for use in the study. Dr. Conor O'Neill from UVM Cancer Center will serve as Principal Investigator, with additional clinical sites expected to join the registry study soon.

RenovoRx (Nasdaq: RNXT), a life sciences company focused on targeted oncology therapies, has scheduled its second quarter 2025 financial results and business highlights conference call for August 14, 2025, at 4:30 p.m. ET.

During the call, management will discuss updates on the RenovoCath device commercialization and the company's Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC). Investors can access the call through a U.S. toll-free number or international line, and a webcast will be available on the company's investor relations website.

RenovoRx (RNXT) reported strong Q1 2025 financial results, marking its first full quarter of RenovoCath® commercial sales with revenue of ~$200,000. The company maintains a solid cash position of $14.6 million, sufficient to fund both RenovoCath commercialization and the ongoing Phase III TIGeR-PaC clinical trial. Over 10 non-trial medical institutions have initiated purchase orders, with repeat orders indicating strong market traction. The company estimates an initial total addressable market of $400 million in peak annual U.S. sales. The Phase III TIGeR-PaC trial has enrolled 91 patients with 56 events recorded, triggering a second interim analysis expected in Q3 2025. Despite progress, the company reported a net loss of $2.4 million compared to $1.1 million in Q1 2024, with increased R&D and SG&A expenses reflecting commercial scale-up investments.

RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025. The presentation will focus on recent business developments, including the commercialization progress of their FDA-cleared RenovoCath drug-delivery device and updates on their Phase III TIGeR-PaC clinical trial.

The trial is evaluating their novel drug-device combination product candidate (intra-arterial gemcitabine) for treating locally advanced pancreatic cancer (LAPC). The fireside chat will be moderated by Scott Henry, AGP Managing Director and Healthcare Analyst, at 12:40 p.m. ET.

RenovoRx (RNXT) has secured a new U.S. patent (No. 12,290,564) for its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. The patent, effective May 6, 2025, covers novel methods for treating tumors by delivering drugs locally near tumor sites after reducing microvasculature in the targeted region. This expands RenovoRx's intellectual property portfolio to 19 issued patents and 12 pending patents, with protection extending through November 2037. The company's RenovoCath®, an FDA-cleared drug-delivery device, began generating revenue in December 2024. RenovoRx is currently conducting a Phase III clinical trial (TIGeR-PaC) evaluating their drug-device combination product for treating locally advanced pancreatic cancer, comparing intra-arterial gemcitabine delivery versus systemic chemotherapy.

RenovoRx (RNXT), a life sciences company focused on targeted oncology therapies and developer of the FDA-cleared RenovoCath drug-delivery device, has scheduled its first quarter 2025 financial results conference call for May 15th, 2025, at 4:30 p.m. ET. Investors can join via phone at 1-877-407-4018 (U.S.) or 1-201-689-8471 (International), or through the webcast available on the company's investor relations website. A replay will be accessible until May 29, 2025, using pin number 13753595.

Johns Hopkins Medicine has joined RenovoRx's Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC) treatment. The trial will evaluate RenovoRx's innovative drug-device combination using intra-arterial gemcitabine delivery via the FDA-cleared RenovoCath device.

Key updates:

• Dr. Valerie Lee appointed as Principal Investigator at Johns Hopkins
• Dr. Michael J. Pishvaian continues as Trial Chairman
• 90 patients randomized with 50 events recorded as of March 28, 2025
• Trial requires 114 total patients and 86 events for final analysis
• Second interim analysis expected in Q2 2025
• Full enrollment targeted for completion in 2025

The study compares RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform against standard intravenous chemotherapy for LAPC treatment. Data Monitoring Committee recommendations are expected in the second half of 2025.